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Abstract
The present paper reports on the results of a systematic study on liposome variables potentially affecting lymphatic
disposition and biodistribution of liposomes after sc injection. Liposomal size was found to be the most important factor
influencing lymphatic uptake and lymph node localization of sc administered liposomes. Lymphatic uptake from the sc
 .   ..injection site of small liposomes about 0.04 mm was relatively high 76% of the injected dose %ID as compared to
large, non-sized liposomes, which remained almost completely at the site of injection. Small liposomes were less efficiently
retained by regional lymph nodes than larger liposomes. Liposomal lipid composition did not influence lymphatic uptake
 .with one exception: Lymphatic uptake was decreased in case of neutral liposomes composed of DPPC . Lymph node
 .localization was substantially enhanced by inclusion of phosphatidylserine PS into the liposomal bilayers. Saturation of
lymphatic uptake and lymph node localization did not occur over a large liposomal lipid dose range, illustrating the efficient
performance of lymph nodes in capturing sc administered particles. q 1997 Elsevier Science B.V.
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1. Introduction
Targeting of particulate carrier systems to the lym-
phatic system has a number of applications including
diagnosis and treatment of diseases with lymphatic
involvement, such as tumor metastases, viral and
bacterial infections, and immunization. The relatively
high absorption of high molecular weight substances
and particulates into the lymphatics after local admin-
 .istration, such as subcutaneous sc , intramuscular
 .  .im and intraperitoneal ip injection, has stimulated
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research on the use of colloidal carriers for lymphatic
drug delivery. Relatively high lymph node localiza-
tion of colloidal particles, such as liposomes, after
local administration has been reported by several
w xresearchers 1–4 . The sc route of administration has
been most extensively investigated for the lymphatic
targeting of liposomes.
Detailed information on factors influencing lym-
phatic uptake and lymph node localization of sc
administered liposomes is not readily available. Al-
though several reports have indicated lymphatic up-
take and lymph node localization of sc administered
liposomes, results are often not comparable as differ-
ent liposome labels, lipid compositions and animals
were used. Moreover, most studies monitored the fate
of the drug rather than that of the particles. Several
reports point to a decreasing lymphatic uptake with
w xincreasing liposome size 5–8 . Only smaller lipo-
 .somes i.e., roughly less than ca. 0.15 mm appear to
enter the lymphatic capillaries, whereas larger lipo-
somes remain at the site of injection. It has also been
observed that the use of small liposomes is beneficial
for achieving a relatively high lymph node localiza-
tion. A few reports deal with the effect of liposome
charge on lymph node localization of sc administered
liposomes. Experiments utilizing liposomes labeled
with 99mTechnetium showed that positively charged
and neutral liposomes localize to a higher extent in
regional lymph nodes than negatively charged lipo-
w xsomes 9 . Similar results were reported by the same
group when using these liposomes for the detection
w xof lymphatic metastases 10 . However, these results
were invalidated later by showing that the technetium
marker did not represent intact liposomes in lymph
w xnodes 11 . The latter study showed that negatively
charged liposomes localized to a greater extent in the
lymph nodes compared to positive liposomes, which
in turn localized better than neutral liposomes. In
contrast, a more recent study on lymph node localiza-
tion of small methotrexate-containing liposomes after
im administration revealed that positive liposomes
localized more in regional lymph nodes as compared
w xto neutral and negatively charged ones 12 .
In general, literature on lymphatic absorption and
lymph node localization of sc administered liposomes
is limited and incomplete. Therefore, a systematic
study on liposomal variables potentially affecting the
in vivo fate of sc administered liposomes was per-
formed. The present paper reports on the effects of
liposomal size, lipid composition and lipid dose on
lymphatic uptake, lymph node localization and dispo-
sition in blood, liver and spleen of sc administered
liposomes.
2. Materials and methods
2.1. Chemicals
 .Egg-phosphatidylcholine EPC , egg-phosphati-
 .dylglycerol EPG , dipalmitoylphosphatidylcholine
 .  .DPPC and dipalmitoylphosphatidylglycerol DPPG
 .were donated by Lipoid Ludwigshafen . Phos-
 .phatidylserine PS was obtained from Avanti Polar
 .  . w 3 xL ipids A labaster, A L . 1 a ,2 a n - H -
 y1.Cholesteryloleylether spec. act. 1.71 TBq mmol
 .was supplied by Amersham Buckinghamshire, UK .
 .  .Cholesterol Chol and 4- 2-hydroxyethyl -1-
 .piperazine-ethane-sulphonic acid Hepes were ob-
 .tained from Sigma St. Louis, MO . Fetal calf serum
 .  .FCS was supplied by Bocknek Canada . Hionic
Fluor, Soluene-350 and Plasmasol were purchased
 .from Packard Downers Grove, IL . All other reagents
were of analytical grade.
2.2. Preparation of radiolabeled liposomes
Liposomes were prepared by the thin film-extru-
w x w3 xsion method 13 . H -Cholesteryloleylether was
added as a marker of the lipid phase. A mixture of
w3 xthe appropriate amounts of lipids, including the H -
label, w as dissolved in a m ixture of
 .chloroformrmethanol 4:1 vrv and evaporated to
dryness by rotation under reduced pressure at 408C.
After flushing the lipid film with nitrogen for at least
20 min, the film was hydrated in a sterile Hepesrglu-
cose-buffer 10 mM Hepes, 1 mM EDTA, 270 mM
.glucose, pH 7.4 . Liposomes were non-sized or sized
by extruding the liposome dispersion through an ap-
propriate combination of single or stacked 0.6, 0.2,
0.1 or 0.05 mm polycarbonate membrane filters
 .Nuclepore; Costar, Cambridge, MA under nitrogen
pressure. Liposomes with a mean size of 0.04 mm
 .were prepared by sonication of small 0.07 mm
liposomes in a bath sonicator Bransonic 5, Branson,
.Tamson, Zoetermeer, The Netherlands for 45 min.
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2.3. Liposome characterization
Radioactivity of the liposomal dispersion was as-
sayed in Hionic Fluor as scintillation mixture and
counted in a Philips PW 4700 liquid scintillation
counter. Mean particle size was determined by dy-
namic light scattering at 258C with a Malvern 4700
 .system using a 25 mW He–Ne laser NEC, Tokyo
and the automeasure version 3.2 software Malvern,
.Malvern, UK . For viscosity and refractive index,
values of the Hepesrglucose buffer were used. As a
measure of particle size distribution of the dispersion,
the system reports a polydispersity index. This index
ranges from 0.0 for an entirely monodisperse up to
1.0 for a polydisperse dispersion.
2.4. Animal experiments
 .Male Wistar rats U:WU, CPB from the animal
facility of Utrecht University with an approximate
body weight of 220 g were used. Animals received
standard laboratory chow and water ad libitum. Rats
w3 xwere injected sc with a single dose of H -labeled
 .liposomes into the dorsal side i.e., the upper side of
the right foot. At various time-points post-injection a
blood sample was drawn from the tail vein. At the
end of the observation period the site of sc injection,
 . w xregional lymph nodes popliteal and iliac 14 , blood,
liver and spleen were collected and assayed for ra-
dioactivity.
2.5. Radioacti˝ity measurements
 .Radioactivity in blood samples 120 ml was deter-
mined by adding 120 ml of Plasmasol, 500 ml of
water and 500 ml of 35% hydrogenperoxide. The
samples were decolorized overnight at 408C. Ra-
dioactivity was assayed in Plasmasol as scintillation
fluid. A total blood volume per rat of 75 ml kgy1
body weight was used for calculation of the percent-
w xage dose in the blood circulation 15 . Lymph nodes,
spleen and the right foot were solubilized completely
in an appropriate amount of Soluene-350 at 408C.
 .Solubilized lymph nodes and samples 500 ml of
solubilized foot and spleen were decolorized with
200 ml of 35% hydrogenperoxide overnight at 408C.
Livers were homogenized in 12 ml of water with a
 .Potter-S homogenizer Braun, Melsungen, Germany .
 .Samples 200 ml of liver homogenate were dissolved
in 1 ml of Soluene-350 and decolorized with 35%
hydrogenperoxide overnight at 408C. Decolorization
of samples was repeated until the samples were only
slightly colored. Radioactivity of the decolorized
samples was assayed in Hionic Fluor as scintillation
fluid.
Lymphatic uptake is defined as the percentage
 .injected dose radioactivity i.e., 100% minus the
percentage of dose radioactivity recovered from the
injection site. Lymph node localization is expressed
as the percentage injected dose radioactivity per gram
 .lymph node tissue popliteal and iliac . Results repre-
 .sent the mean of 4 rats"standard deviation sd .
2.6. Pharmacokinetics
All pharmacokinetic parameters were calculated
using the curve fitting program KINFIT MEDI_
.WARE, Groningen, The Netherlands for each ani-
mal individually. Mean and sd were calculated for
each treatment group.
2.7. Statistics
The effect of different treatments was evaluated by
ANOVA with 95% confidence interval. Differences
were considered significant when the p-value was
less than 0.05.
3. Results
3.1. Reference liposomes
A single dose of small liposomes mean size about
.0.07 mm with the composition EPC:EPG:Chol
 . 10:1:4 molar ratio referred to as ‘reference lipo-
.somes’ , was sc administered to rats at a dose of 2.5
 .mmol total lipid TL . Liposomes were radiolabeled
w3 xwith a tracer amount of H -cholesteryloleylether
which has proven to be a reliable label to monitor the
w xfate of liposomes in vivo 16,17 . The dorsal side of
the foot was chosen as site of sc injection as injection
of liposomes into this site of rats results in relatively
high lymphatic uptake as compared to sc administra-
w xtion into the flank 18 . The in vivo fate of the
liposomes was studied over a period of 52 h post-in-
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jection. For comparative reasons, quantitative data
obtained with the reference liposomes, serve as a
reference for data obtained with liposomes of differ-
ent size and composition.
Judging from the results presented in Fig. 1A,
lymphatic uptake i.e., the percentage of injected
dose taken up from the sc injection site by the
.draining lymphatic capillaries of the reference lipo-
Fig. 1. Biodistribution of sc administered reference liposomes. A single dose of reference liposomes EPC:EPG:Chol, 10:1:4 molar ratio,
.mean diameter 0.07 mm, 2.5 mm TL was injected sc into the dorsal side of the foot of rats. Recovery of liposomal label was determined
 .  .at several time-points post-injection. A Percentage of injected dose recovered from the sc injection site. B Percentage of injected dose
 .  .per g tissue recovered from the regional lymph nodes. C Percentage of injected dose circulating in the total blood volume. D
 .  .  .Percentage of injected dose per g tissue recovered from liver ‘ and spleen v . E Comparison of percentage of injected dose per g
tissue in regional lymph nodes, liver and spleen. Values represent the mean percentage"sd of 4 animals.
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somes occurred over the first 12 h after injection.
After this initial period, the absorption process was
 .completed with about 40% of the injected dose %ID
remaining at the injection site. Consistent with the
time frame over which lymphatic uptake occurred,
lymph node localization i.e., the percentage of in-
jected dose radioactivity per gram lymph node tissue
 y1..%ID g reached a maximum value of about
y1  .120%ID g i.e., 1.2%ID over a period of 12 h
 .after injection Fig. 1B . Levels of radioactivity did
not change significantly over the subsequent 40 h.
Liposome localization was negligible in lymph nodes
not involved in drainage of the injection site and in
control lymph nodes on the left, non-treated side of
the body.
Blood levels of radiolabeled liposomes are pre-
sented in Fig. 1C. The peak blood level about
.35%ID was reached about 6 h post-injection. At the
end of the observation period, i.e., 52 h after injec-
tion, liposomal radioactivity in the blood had de-
clined to levels less than 5%ID. When plasma and the
cellular fraction were separated, all radioactivity in
blood was associated with the plasma fraction. Lipo-
somal label recovery from liver and spleen is pre-
sented in Fig. 1D. In line with the observations on the
kinetics of lymphatic uptake and lymph node local-
ization, the majority of the recovered liposomal label
localized in liver and spleen about 30 and 2%ID,
y1 .respectively, i.e., 3%ID g for both organs during
the initial 12 h after injection. The biodistribution
pattern did not change significantly over the subse-
 .quent period of 52 to 96 h results not shown . A
comparison of the degree of localization in regional
lymph nodes, liver and spleen at the end of the
 .observation period i.e., 52 h post-injection is shown
in Fig. 1E. Clearly, when the data are expressed as
the percentage injected dose per g tissue, lymph node
localization was much higher than localization in
 .liver and spleen 40- and 31-fold higher, respectively .
3.2. Influence of dose
To study if lymphatic uptake and lymph node
localization depend on lipid dose, liposomes with the
same composition as reference liposomes but some-
 .what larger mean size 0.10 mm , were administered
sc into the foot of rats in escalating lipid doses i.e.,
2 3 4 .10, 10 , 10 and 10 nmol TL . For each of the
liposome doses investigated, about 60%ID was re-
covered at the site of injection 52 h post-injection
 .results not shown . The absolute amount of lipid
recovered from the injection site is presented in Fig.
2A. The straight line indicates that no saturation of
the lymphatic absorption process was observed over
the dose range investigated. The same observation
 .applies for lymph node localization Fig. 2B . The
absolute amount of liposomal label recovered from
lymph nodes 52 h after injection increased almost
linearly with increasing liposome dose. The same
linear relationship was found for large, non-sized
Fig. 2. Influence of dose on lymphatic uptake and lymph node
 .localization of small liposomes. A single dose of small 0.10 mm
 .liposomes EPC:EPG:Chol, 10:1:4 molar ratio was injected sc
into the dorsal side of the foot of rats in escalating lipid dose
 2 3 4 .i.e., 10, 10 , 10 , 10 nmol TL . Levels of radioactivity at the
site of injection and in regional lymph nodes were determined 52
 .h post-injection. A Absolute amount of total lipid taken up from
 .the sc injection site. B Absolute amount of total lipid recovered
from regional lymph nodes. Values represent the mean percent-
age"sd of 4 animals.
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 .liposomes at the same dose range results not shown .
Moreover, repeated injections of small liposomes 1
injection of 3.5 mmol TL given daily over 4 subse-
.quent days , also resulted in a linear dose-dependency
of the accumulation of liposomes in regional lymph
 .nodes results not shown .
Fig. 3. Influence of size on the pharmacokinetics and biodistribution of sc administered liposomes. A single dose of liposomes
 .EPC:EPG:Chol, 10:1:4 molar ratio, 2.5 mmol TL of varying size was injected sc into the dorsal side of the foot of rats. Levels of
 .  .radioactivity were determined 52 h post-injection. A Percentage of injected dose recovered from the sc injection site. B Percentage of
 .injected dose per g tissue recovered from the regional lymph nodes. C Percentage of the lymphatically absorbed fraction per g recovered
 .  .from the regional lymph nodes. D Percentage of injected dose circulating in the total blood volume. E Percentage of injected dose per
 .  .g tissue recovered from liver 9 and spleen I . Values represent the mean percentage"sd of 4 animals.
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3.3. Influence of size
Liposomes with the same lipid composition as
reference liposomes but with varying mean size were
injected sc at a dose of 2.5 mmol TL. Liposomes
were either non-sized, or had a mean diameter of
0.40, 0.17, 0.07 or 0.04 mm referred to as 0.40,
.0.17, 0.07 or 0.04 mm liposomes . The degree of
lymphatic uptake was found to be negatively corre-
 .lated with liposome size Fig. 3A . Over a time
period of 52 h after injection, 0.04 mm liposomes
were taken up by the lymphatics to a relatively high
 .extent 74%ID , whereas large, non-sized liposomes
remained almost completely localized at the site of
injection.
Remarkably, lymph node localization depended
only slightly on liposome size. Lymph node localiza-
tion was found to be between 70 and 130%ID gy1
 .for all sizes investigated Fig. 3B and was slightly
lower for larger liposomes. It should be realized,
however, that, as lymphatic uptake decreases with
 .increasing liposome size Fig. 3A , the fraction of
injected liposomes reaching regional lymph nodes is
much higher for smaller liposomes than for larger
liposomes. Consequently, lymph node localization
should be corrected for the lymphatically absorbed
fraction i.e., the difference between administered
.dose and amount recovered at the injection site to
establish the true efficiency of lymph node localiza-
tion of the different liposome types. Therefore, the
‘relative lymph node localization’ was calculated by
correcting the percentage of dose recovered in the
lymph nodes for the lymphatically absorbed fraction
 .Fig. 3C . It was found that the relative lymph node
localization of small liposomes was much less as
compared to the relative lymph node localization of
larger liposomes. Only 120%ID gy1 of the absorbed
fraction of 0.04 mm liposomes localized in regional
lymph nodes, whereas more than 1000%ID gy1 of
the absorbed fraction of large, non-sized liposomes
 .localized in regional lymph nodes Fig. 3C . Interest-
ingly, determination of lymph node localization at
several time-points post-injection over a time-period
of 52 h, revealed that the maximum lymph node
concentration of the large, non-sized liposomes was
reached within 1 h without any significant change
 .thereafter results not shown .
Concentrations of liposomes in blood and liver are
in agreement with the observed pattern of size depen-
dency of lymphatic absorption, as increased lym-
phatic absorption translated into increased blood lev-
 .  .els Fig. 3D and higher liver uptake Fig. 3E . In
contrast to localization in the liver, the extent of
splenic localization was not positively correlated with
 .the extent of lymphatic absorption Fig. 3E .
3.4. Influence of lipid composition
The effects of liposomal charge negative charge
. conferred by PG or PS and bilayer fluidity as a
result of the presence of cholesterol or the use of
.phospholipids with different degree of saturation on
lymphatic delivery of sc administered liposomes was
studied utilizing liposomes with the lipid composi-
tions listed in Table 1.
Lymphatic uptake from the injection site was inde-
pendent of the presence of charged lipid, the presence
of cholesterol, and bilayer fluidity as compared to
 .lymphatic uptake of reference liposomes Fig. 4A .
DPPC-liposomes showed a different behavior as
compared to reference liposomes; lymphatic uptake
of these liposomes was decreased to less than half of
the uptake of reference liposomes. Lymph node local-
ization was found to be independent of cholesterol
content, the presence of EPG and bilayer fluidity.
DPPC-liposomes and PS-containing liposomes local-
 .ized in lymph nodes to a higher extent ca. 3-fold
 .than reference liposomes Fig. 4B .
The time course of blood levels induced by the sc
injection of the various types of liposomes is shown
Table 1
Liposomal lipid compositions studied
Lipid composition Molar ratio
 .EPC:EPG:Chol reference liposomes 10:1:4
EPC:EPG 10:1
EPC:Chol 10:4
EPC
EPC:PS:Chol 10:1:4
EPC:PS 10:1
DPPC:DPPG:Chol 10:1:4
DPPC
 .Compositions of small 0.07 mm liposomes used to study the
influence of the effect of liposomal charge and bilayer fluidity on
the lymphatic uptake, lymph node localization and biodistribution
after sc injection.
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Fig. 4. Influence of composition on the pharmacokinetics and biodistribution of sc administered liposomes. A single dose of small
 .liposomes mean diameter 0.07 mm, 2.5 mmol TL of varying composition was injected sc into the dorsal side of the foot of rats. Levels
 .  .of radioactivity were determined 52 h post-injection. A Percentage of injected dose recovered from the sc injection site. B Percentage
 .of injected dose per g tissue recovered from the regional lymph nodes. C Percentage of injected dose circulating in the total blood
 .  .  .volume at several time-points after injection. D Percentage of injected dose per g tissue recovered from liver 9 and spleen I .
Values represent the mean percentage"sd of 4 animals.
Table 2
Effect of FCS on liposomal size in vitro
 .  .Lipid composition molar ratio Mean size nm Polydispersity index
Before After Before After
 .EPC:EPG:Chol 10:1:4 reference liposomes 71"1 65"1 0.22"0.02 0.20"0.02
EPC 70"0 70"1 0.20"0.03 0.20"0.02
 .DPPC:DPPG:Chol 10:1:4 75"2 73"2 0.15"0.06 0.22"0.03
a aDPPC 67"1 115 "6 0.25"0.03 0.44 "0.02
 .Small liposomes with a mean size of about 0.07 mm and a polydispersity index -0.1 were incubated in 80% FCS 15 mM TL for 24 h
at 378C. Data represent the mean size and polydispersity index"sd of 3 dispersions; before: immediately after mixing with the
incubation medium and after: 24 h after incubation.
a p-0.01.
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in Fig. 4C. The liposome levels in blood after admin-
istration of PS-containing liposomes and DPPC-lipo-
somes were strikingly low as compared to those of
the other liposome types, which all showed a blood
concentration-time profile with a clear absorption and
distribution–elimination phase. Uptake in liver and
spleen is presented in Fig. 4D. Liver uptake for all
liposome types was about the same. Regarding splenic
uptake, concentrations of PS-containing liposomes
were 3-fold higher as compared to reference lipo-
somes. Splenic uptake of DPPC-liposomes was in-
 .creased slightly 1.5-fold . The other liposome types
did not differ significantly from the reference lipo-
somes with regard to the degree of splenic localiza-
tion.
As DPPC-liposomes showed a substantially de-
creased lymphatic uptake as compared to reference
 .liposomes Fig. 4A , it was hypothesized that DPPC-
liposomes might aggregate at the site of injection. To
approach this hypothesis experimentally, the aggrega-
tion behavior of DPPC-liposomes incubated with FCS
in vitro was investigated. An increased particle size
and polydispersity was seen only with DPPC-lipo-
 .somes Table 2 .
4. Discussion
Several studies have demonstrated the potential of
liposomes as ‘lymphotropic’ drug delivery systems
for targeting to regional lymph nodes after sc admin-
w xistration 2,3,7 . The majority of the published data
were obtained by following the fate of liposome-en-
capsulated drugs after sc administration. It should be
realized however, that liposome-encapsulated drugs
may influence the fate of liposomes in vivo and may
be distributed differently than the liposomal carrier
after release from the liposomes. Also, the influence
of physicochemical properties of the liposomal car-
rier, such as liposome size and lipid composition, on
‘lymphotropic’ behavior has not been described in
detail yet. With greater understanding of the biodistri-
bution of the drug carrier, the fate of the encapsulated
drug may be anticipated more easily. The present
study deals with a systematic investigation of factors
potentially influencing lymphatic disposition of sc
administered liposomes.
Sc injection of reference liposomes into the dorsal
side of the foot of rats, resulted in an initial 12 h
period of lymphatic uptake from the site of injection.
After this 12 h time-period lymphatic uptake ap-
peared to be finished with about 40%ID remaining at
 .the injection site Fig. 1A . A possible explanation
for the incomplete uptake might be the heterogeneous
size distribution of the liposome dispersion with lipo-
somes substantially larger than the mean size of 0.07
mm being retained at the site of injection. Another
explanation relates to an alteration of the interstitial
pressure during the initial period of uptake. As lym-
phatic absorption from the injection site may be the
result of an elevated interstitial pressure caused by
w xthe injection itself 18 , lymphatic absorption may
stop when the interstitial pressure is normalized. A
third possibility is aggregation of liposomes at the
site of injection resulting in the formation of large
aggregates that are not taken up by the lymphatic
capillaries.
Once liposomes have traversed the interstitium and
entered the lymphatic capillaries, they pass through
the lymphatic system where they can be captured in
regional lymph nodes. The time frame over which
lymph node localization occurs is in line with the
observed time frame of occurrence of lymphatic up-
take, i.e., the initial 12 h after administration Fig.
.1B . Lymph node localization of reference liposomes
in regional lymph nodes was about 30- to 40-fold
higher than uptake in spleen and liver, the natural
 .target organs for circulating liposomes Fig. 1E .
Considering the fact that liposomes will encounter
lymph nodes only once when passing through on
their way to the blood circulation and do not have, as
in the case of liver and spleen, the possibility of
multiple passage, lymph node localization of lipo-
somes is apparently an efficient process. It was of
interest to determine at which lipid dose saturation of
lymph nodes occurs. Therefore, lymphatic uptake and
lymph node uptake was studied over a large liposo-
 4 .mal lipid dose range 10–10 nmol TL . Saturation
of lymphatic uptake and lymph node localization did
 .not occur over the dose range investigated Fig. 2 .
Together with the observation of efficient capture
process, this observation of high capacity to retain
particulate matter illustrates the suitability of the sc
route for lymph node targeting of particulates.
Obviously, if lymphatic drug delivery is the main
goal, lymphatic uptake is an important parameter
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determining the absolute amount of liposomes arriv-
ing in the regional lymph nodes. In line with findings
of others, it appears that size is the most crucial
wfactor influencing lymphatic uptake of liposomes 6–
x8,10 . Small liposomes, with a mean size smaller than
0.1 mm, were taken up into the lymphatic capillaries
to a high extent, whereas lymphatic uptake clearly
declined with an increasing mean liposome size Fig.
.3A . The size-dependent uptake is likely to be related
to the process of particle transport through the inter-
stitium. The structural organization of the interstitium
dictates that the diameter of administered particles
should be small enough to allow migration through
the aqueous channels in the interstitium. Therefore,
larger particles will have more difficulty to traverse
the interstitium and will remain at the site of injection
to a large, almost complete extent.
Following lymphatic uptake, liposomes pass
through a system of lymphatic vessels and will en-
counter one or more lymph nodes where a fraction
will be retained. Liposomes may accumulate in re-
gional lymph nodes as a result of simple mechanical
filtration in the intranodal meshwork of the lymph
node or by phagocytosis by lymph node macrophages
w x y119 . When expressed as %ID g , lymph node local-
ization was about the same for all liposome sizes
 .evaluated Fig. 3B . However, this result should not
lead to the conclusion that liposome size does not
affect lymph node localization. When expressed as
the percentage of the lymphatically absorbed fraction
 .relative lymph node localization , lymph node local-
ization is much higher for larger liposomes than for
 .smaller liposomes Fig. 3C . Evidently, larger lipo-
somes are retained more efficiently by lymph nodes
than smaller liposomes, most probably because larger
liposomes are likely to be filtered out more effi-
ciently in lymph nodes than smaller liposomes. Also,
in view of the outcome of studies on the interaction
between liposomes and macrophages, larger particles
may be phagocytosed more efficiently by
w xmacrophages than smaller particles 20 . Both mecha-
nisms may have contributed to the enhanced lymph
node localization of large liposomes as compared to
small liposomes. The observation of relative high
lymph node localization of large particles as com-
pared to small liposomes is in line with results ob-
tained after ip injection of liposomes as reported by
w xHirano and Hunt 1 .
The extent of lymphatic uptake and lymph node
localization of particles after sc administration has
been shown to be influenced by surface character-
istics of injected particles and components of the
w xinterstitium and lymph 21 . Therefore, lipid composi-
tion should be considered as another factor influenc-
ing lymphatic uptake and lymph node localization of
sc administered liposomes. The present results, how-
ever, do not point to lipid composition as a factor of
importance for lymphatic uptake, with one exception:
DPPC-liposomes were absorbed from the injection
site to a much lesser extent than the other composi-
 .tions investigated Fig. 4A . The low lymphatic up-
take of DPPC-liposomes is probably related to a
strong tendency of these liposomes to aggregate. The
observed tendency of DPPC-liposomes to grow in
 .size during incubation with FCS Table 2 supports
the view that aggregation at the injection site may
have limited lymphatic uptake of liposomes after sc
administration.
Also lymph node localization was not strongly
affected by the liposomal lipid composition. Only
PS-containing liposomes and DPPC-liposomes be-
haved differently as compared to reference liposomes
 .Fig. 4B . It was observed that PS-containing lipo-
somes localized to a much higher extent in regional
lymph nodes than reference liposomes. It has been
shown that PS-exposure serves as a signal for trigger-
w xing recognition by macrophages 22 . Presumably, the
substantially increased lymph node localization of
PS-containing liposomes may be attributed to the
same mechanism. Remarkably, also lymph node lo-
calization of DPPC-liposomes was increased as com-
pared to reference liposomes. This observation is
probably not related to preferential uptake by lymph
node macrophages, as liposomes with rigid bilayers
are known to be less susceptible to uptake by
w xmacrophages 20 . As hypothesized above, DPPC-
liposomes may have aggregated at the site of injec-
tion as well as during the process of lymphatic
absorption and transport to regional lymph nodes.
Aggregation may have yielded a bigger fraction of
larger particles in lymph which may explain the
 .observed higher lymph node localization Fig. 4B .
Once liposomes have been taken up by the lym-
phatic capillaries and passed through regional lymph
nodes, they reach the general circulation where they
 .behave as if administered by the intravenous iv
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route. Administration of reference liposomes resulted
in a peak blood level of about 35%ID at about 6 h
 . w3 xafter injection Fig. 1C . When H -labeled reference
liposomes labeled with an additional hydrophilic
w125 x .marker I -tyraminylinulin were injected sc, the
hydrophilic label followed the same pattern of distri-
bution as the lipid marker, suggesting that the lipo-
somes reach the blood circulation intact and are
capable of transporting hydrophilic drugs from the sc
injection site into the general circulation results not
.shown . Following administration of the large, non-
sized liposomes, radioactivity in blood was not de-
 .tectable Fig. 3D , which is in line with the negligible
 .lymphatic uptake of these liposomes Fig. 3A . Also
after administration of 0.40 mm liposomes with the
same composition as reference liposomes, 0.07 mm
DPPC- and PS-containing liposomes blood levels of
radioactivity were negligible. However, considerable
lymphatic uptake 17, 23 and 55–60%ID, respec-
. tively of the latter liposome types was observed Fig.
.3AFig. 4A . Apparently, for these liposomes the rate
of elimination from the blood is faster than the rate of
entry via the lymphatics.
In summary, liposomal size is the most important
factor influencing lymphatic uptake and lymph node
localization of sc administered liposomes. Small lipo-
somes were taken up to a high extent, whereas large,
non-sized liposomes remained almost completely at
the site of injection. The opposite holds true for the
degree of lymph node localization of absorbed lipo-
somes as large liposomes are more efficiently re-
tained by lymph nodes than small liposomes. Liposo-
mal lipid composition did not appear to influence
lymphatic uptake significantly, except in the case of
neutral liposomes composed of DPPC. Decreased
lymphatic uptake of DPPC-liposomes is possibly the
result of spontaneous aggregation at the injection site.
Lymph node localization was substantially enhanced
by inclusion of PS into the liposomal bilayers, sug-
gesting an important role of macrophages in lymph
node localization of sc administered liposomes. Fur-
thermore, saturation of lymphatic uptake and lymph
node localization did not occur over a large liposomal
lipid dose range, illustrating the efficient performance
of lymph nodes in capturing sc administered parti-
cles. The results presented in this paper establish the
significance of sc administration of liposomes in
achieving high liposome levels in regional lymph
nodes, and are relevant for the design of liposomes
with optimal lymphotropic characteristics for drug
targeting, diagnostic and immunization purposes.
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